Next Article in Journal
The Influence of Iron-Deficiency Anaemia (IDA) Therapy on Clinical Outcomes and Healthcare Resource Consumptions in Chronic Kidney Disease Patients Affected by IDA: A Real-Word Evidence Study among the Italian Population
Next Article in Special Issue
Acute Changes in Serum Creatinine and Kinetic Glomerular Filtration Rate Estimation in Early Phase of Acute Pancreatitis
Previous Article in Journal
Speech Discrimination in Infancy Predicts Language Outcomes at 30 Months for Both Children with Normal Hearing and Those with Hearing Differences
Previous Article in Special Issue
Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 11
Issue 19
10.3390/jcm11195822
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Effects of Race on Acute Kidney Injury

by
Muzamil Olamide Hassan
1,2 and
Rasheed Abiodun Balogun
3,*
1
Department of Medicine, Obafemi Awolowo University, Ile-Ife 220005, Nigeria
2
Division of Nephrology, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa
3
Division of Nephrology, Department of Medicine, University of Virginia, Charlottesville, VA 22908, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2022, 11(19), 5822; https://doi.org/10.3390/jcm11195822
Submission received: 8 August 2022 / Revised: 16 September 2022 / Accepted: 27 September 2022 / Published: 30 September 2022
(This article belongs to the Special Issue Clinical Advances in Kidney Failure)
Browse Figure
Review Reports Versions Notes

Abstract

Racial disparities in incidence and outcomes of acute kidney injury (AKI) are pervasive and are driven in part by social inequities and other factors. It is well-documented that Black patients face higher risk of AKI and seemingly have a survival advantage compared to White counterparts. Various explanations have been advanced and suggested to account for this, including differences in susceptibility to kidney injury, severity of illness, and socioeconomic factors. In this review, we try to understand and further explore the link between race and AKI using the incidence, diagnosis, and management of AKI to illustrate how race is directly related to AKI outcomes, with a focus on Black and White individuals with AKI. In particular, we explore the effect of race-adjusted estimated glomerular filtration rate (eGFR) equation on AKI prediction and discuss racial disparities in the management of AKI and how this might contribute to racial differences in AKI-related mortality among Blacks with AKI. We also identify some opportunities for future research and advocacy.

1. Introduction

Race can be defined “as a hierarchal human-grouping system, generating social classifications to identify, distinguish and marginalize some groups across nations, regions and the world. Race divides human populations into groups often based on physical appearance, social factors and cultural backgrounds” [1]. Race is a socio-political concept that is inseparably linked to health outcomes in individuals from minority racial status worldwide [2]. Race is not a biological concept.
Racial disparities in clinical outcomes of several health conditions are very common [3]. Such disparities have been reported in AKI, where Black race is associated with a higher risk of AKI compared to non-Black race [4]. Moreover, the prevalence of dialysis-requiring AKI is increasing annually, and Black race is an independent risk factor for initiation of dialysis in AKI patients [4,5,6,7,8]. This phenomenon is thought to be due to the close interplay of clinical, socioeconomic, and genetic risk factors [9], which are driven by structural racial category [10].
Acute kidney injury describes the sudden loss of kidney function, characterized by ≥0.3 mg/dL (≥26.5 μmol/L) rise in serum creatinine within 48 h or an increase in serum creatinine ≥1.5 times over baseline, which is known or presumed within the prior 7 days, or reduced urinary output of < 0.5 mL/kg/h within 6 h [11]. Given that AKI has significant clinical consequences, including higher hospitalization rates, increased hospital length of stay, increased in-hospital and post-hospitalization mortality, and higher risk of progression to chronic kidney disease [12,13,14,15], understanding and addressing how race directly affects patients with AKI is crucial to improving the diagnosis, treatment, and outcomes of AKI in minority racial groups.
In this review, we use the incidence, diagnosis, and management of AKI to illustrate how race is directly related to AKI outcomes, with a focus on Black and White individuals with AKI. We examine racial disparities in COVID-19-related AKI. In particular, we explore the effect of a race-adjusted estimated glomerular filtration rate (eGFR) equation on AKI prediction and discuss racial disparities in the management of AKI and how this might contribute to racial differences in AKI-related mortality among Blacks with AKI.

2. Racial Disparities in the Incidence of AKI

Previous studies have reported that Black patients have a disproportionately higher risk of AKI when compared with White patients [4,8,16,17,18,19,20,21,22]. Using self-reported Black and White participants from the Atherosclerosis Risk in Communities (ARIC) study, Grams et al. [4] investigated the impact of race on the incidence of AKI-related hospitalizations. The authors in the large, prospective, community-based studies involving 10,588 African-American and Caucasian participants followed up for 13 years reported significantly higher incidence of AKI in Blacks, with a 30% higher risk in Blacks compared to Whites. After a sequential multivariable model, the risk increased to 50% following the inclusion of age and sex, suggesting that Blacks are at a greater risk of AKI despite their younger age. However, the risks were not significantly different among those participants with major mediators such as obesity, diabetes, or hypertension, which are more common in Blacks compared to Whites. The authors further showed that the relationship between race and AKI was significantly weakened with adjustment for socio-economic indicators such as access to health insurance and total annual family income.
Similarly, other studies have reported significantly higher incidence of AKI along racial lines among specialized populations, including patients with diabetes [17], trauma [20], and those undergoing procedures such as percutaneous coronary intervention [8,21] and knee surgery [19].
In contrast to the findings of Grams et al. [4] in the ARIC study, Muiru and his colleagues, in the Chronic Renal Insufficiency Cohort (CRIC) Study, a multicenter prospective study, observed that Blacks had a 22% greater hazard for AKI hospitalization than the Whites, and showed that the racial disparities in AKI were due to the differences in prehospitalization baseline clinical risk factors such as diabetes, blood pressure, and proteinuria [22]. Thus, this suggested that the increased risk of AKI among Black individuals may be mitigated through targeted screening and tighter control of blood pressure to lower proteinuria. Taken together, all these findings highlight the need for future studies to untie the “Gordian knot” between socio-economic determinants of AKI from those that might be biologic, if any.
Moreover, according to the 2018 USRDS annual data report [23], using data from the Medicare, ClinformaticsTM, (OptumInsight, Eden Prairie, MN, USA) and Veterans Affairs patient population, a higher proportion of Black patients had AKI compared to Whites or Asians. Among Medicare patients aged 66 years and older, AKI incidence rates were 34.3%, 23%, and 25.9% in Black, White, and Asian patients, respectively, and for Optum Clinformatics™ (OptumInsight, Eden Prairie, MN, USA) patients aged 22 years and older, the incidence of AKI among Black, White, and Asian patients was 9.4%, 7.4%, and 3.3%, respectively. The hospitalized Veterans Affairs populations showed a similar trend—the incidence of AKI was 30.4%, 24.1%, and 24.2% among Black, White, and Asian Americans, respectively. These data therefore highlight differences in AKI incidence by race. Table 1 summarizes the evidence related to the incidence, management, and outcome of AKI in Black and White races.

3. Race, APOL1 Status, and Incidence of AKI

Considering the well-established genetic susceptibility for kidney disease among Black populations [33,34], it was not surprising that Privratsky et al. [35] demonstrated a greater-than-two-fold rise in postoperative serum creatinine among Black patients with high-risk APOL1 status undergoing cardiac surgery. However, a previous study by Grams et al. [4] showed that APOL1 high-risk variant was not significantly associated with higher risk of AKI. This study was limited by reliance on billing codes to ascertain AKI, thereby resulting in ill-defined AKI phenotypes. Given that there are several recent reports of association between high-risk APOL1 status and increased risk of AKI among patients infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) [35,36,37,38,39,40,41], further studies are needed to elucidate APOL1 biology, its role in well-defined AKI cases, and its possible modifying effect on progression to CKD after injury.

4. Race and COVID-19-Related AKI

Acute kidney injury is a well-recognized complication of SARS-CoV-2 infection, with an incidence rate of 20% among hospitalized patients and greater than 50% among the critically ill patients [42]. Since the first case of SARS-CoV-2 infection which causes coronavirus disease 2019 (COVID-19) was reported in Wuhan, China, racial disparities in the development, severity, and outcomes of this disease have become increasingly reported [43,44,45]. According to the Centers for Disease Control, Blacks had a 1.1 times higher rate of COVID-19 patients, 2.3 times higher rate of COVID-19 hospitalization, and 1.7 times higher COVID-19 mortality rate than Whites [46]. Accordingly, several previous studies have reported that Black patients with COVID-19 had approximately 1.2–2.2 times increased odds of developing in-hospital AKI compared to their White counterparts [47,48,49,50]. Even though the exact mechanism of racial disparities in risk of COVID-associated AKI is yet to be elucidated, some possible mechanisms have been proposed. Genetic polymorphisms involving ACE2, IL-6, and AChE genes are closely associated with higher burden of COVID-19 disease and these gene polymorphisms have been shown to be more common in Black individuals [51,52]. In addition, Black populations are exposed to a higher risk of vitamin D deficiency, and it has been proposed that Vitamin D plays a protective role against COVID-19 infectivity and severity through its ability to modulate the immune system by suppressing T helper-1 functions and potentiating expression of the regulatory T cells, thereby causing less severe cytokine storm [53,54]. Hence, Black patients may face higher risk of cytokine storm and associated systemic and intrarenal inflammation. Table 2 summarizes studies highlighting association between race and COVID-19-induced AKI.

5. Race-Adjusted eGFR and AKI Prediction

The use of race-adjusted eGFR is controversial in nephrology [58]. Low eGFR is a strong predictor of AKI and is routinely used by clinicians to predict the risk of AKI following contrast-related procedures [59]. Traditionally, eGFR is estimated using the Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula that includes a correction factor for Black race [60,61]. Remarkably, the inclusion of the race correction factor in the eGFR equation is methodologically flawed because it does not take into account the ancestral diversity among Black patients and patients with mixed racial background, and the fact that it is subjective as a result of self-identification of race. Consequently, in recognition of the fact that race is a social construct with only limited utility in medicine, the National Kidney Foundation and the American Society of Nephrology have now recommended the removal of the race correction factor in eGFR calculation [62], necessitating exclusion of race variables in the new eGFR equations that are currently being developed [63]. In a preprint research study, which used data from the American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) CathPCI Registry, Huang and his colleagues demonstrated the impact of removing race from eGFR equations for predicting AKI. The authors showed that the inclusion of the race correction factor significantly underestimated risk for AKI among Black populations (predicted 7.6% vs. observed 10.2%) while marginally overestimating AKI risk among the non-Black population (predicted 7.4% vs. observed 7.1%). However, when the race correction factor was removed, the underestimation of AKI risk was partially corrected among Black patients (predicted 8.2%), and the underestimation was further reduced (predicted 10.1%) by including race as an independent predictor in the AKI model [64]. Hypothetically, eliminating race correction factor from eGFR equations can potentially influence diagnostic and treatment decisions that will take into account each patient’s body habitus, comorbidities, and lifestyle considerations [65,66].

6. Racial Disparities in the AKI-Related Mortality

Even though African Americans (Blacks) in the general population are at a higher risk of cardiovascular and non-cardiovascular mortality when compared to Whites [67,68], several reports have suggested that a paradox exists for individuals with AKI, with Black patients having better survival rates than their White counterparts [15,26,69]. Waikar et al. [26], in their study of hospitalized acute renal failure patients between 2000 and 2003 using the Nationwide Inpatient Sample, showed a survival advantage among Black patients with AKI compared to their White counterparts, with Black patients having 16% (95% confidence interval, 10–20%) lower odds for death than White patients with AKI. In our study that included data of 11,567 AKI patients managed at the University of Virginia Health System, we demonstrated that Black patients had lower in-hospital mortality than Whites, with adjusted odds ratio 0.82, 95% confidence interval 0.70–0.96, p = 0.0015. Following further analysis, we also extended the findings of the previous workers by demonstrating Black patients had lower 90-day post-hospitalization mortality and better long-term survival advantage when compared to their White counterparts [15]. Similarly, data from the United States Renal Data System (2021 USRDS Annual Data Report) also showed a survival advantage for Black populations compared to White populations after 24 months’ follow-up; Black patients had 38,6% death rates compared to 41.7% death rates in White patients. Previously postulated explanations for this paradoxical finding such as increased access to health care due to medical insurance, “reverse epidemiology” of cardiovascular risk factors, differences in susceptibility to kidney injury, severity of illness, or the response to uremia, warrant additional well-designed investigation [15,26].
Interestingly, like AKI patients, Black patients with end-stage renal disease (ESRD) had also been documented to have lower mortality rates than Whites, and many well-described mediators of paradoxical survival advantage observed among ESRD patients may also be relevant in AKI patients. Most importantly, the similar findings of improved survival for Black patients with AKI and ESRD compared to White patients may suggest that the response to uremia or its treatment may vary by race [26]. Furthermore, previous studies have documented racial differences in biologic processes underlying the pathogenesis of AKI and ESRD, such as interactions between APOL1 genotype and cause of kidney disease [70], abnormalities in endothelial functions [71,72], oxidative stress [73], and inflammation [74]. It is plausible that these biologic factors may account for the paradoxical survival advantage by AKI/ESRD status among Black patients. Further population-based genetic studies in AKI and ESRD patients are warranted to confirm these findings.

7. Racial Disparities in the Management of AKI

Patients with AKI are at increased risk of progressive chronic kidney disease (CKD) [75], including ESRD, where they are exposed to additional racial health disparities that impact on AKI outcomes. In addition to facing AKI-related racial disparities, compared to White patients, Black patients receive less intensive hemodialysis and inferior hemodialysis access [76], and are less likely to be offered renal transplantation [77]. Socioeconomic status and limited access to healthcare play a role regarding the racial inequities in the treatment and outcomes of kidney disease. For example, as a result of low income, poor access to healthcare, and lack of health insurance, late referral of Black and/or poor patients with kidney disease for care by a nephrologist prevents these patients from receiving optimal care [78,79]. Figure 1 illustrates how sociocultural factors influences racial/ethnic minority health with implications for progression of AKI to CKD/ESRD.
Notably, attempts have been made recently to improve the quality of healthcare with efforts targeted at eliminating racial and ethnic disparities in health, and this may have major implications for the prevention, diagnosis, and treatment of kidney disease [80,81,82]. Mortality rates in patients with AKI remain high in spite of the skyrocketing cost of the health insurance-funded program. It is conceivable that elimination of these racial disparities would improve outcomes in patients with AKI.
In conclusion, the racial disparities in the incidence, social and biologic determinants, diagnosis, and outcomes of AKI are well-documented and vary between Black and White populations. Disparities in health outcomes as a result of socioeconomic status are discriminating and unjust. Therefore, it is very important to disentangle socioeconomic determinants of AKI such as individual-level income, education, and insurance from those that are biologic risk factors such as diabetes, hypertension, obesity, and cardiovascular disease, which are pervasive in Black populations. Moreover, in order to improve the healthcare of disenfranchised ethnic minorities globally, it is imperative to address lingering racial and ethnic health disparities across the spectrum of kidney disease that continue to perpetuate limited educational opportunities, socioeconomic imbalances, and limited access to healthcare delivery to improve health outcomes of disadvantaged racial minorities with AKI.

Author Contributions

Conceived and designed the manuscript: M.O.H. and R.A.B. Contributed to the writing of the manuscript: M.O.H. and R.A.B. Conceptualization, M.O.H. and R.A.B.; methodology, M.O.H. and R.A.B.; writing—original draft preparation, M.O.H.; writing—review and editing, M.O.H. and R.A.B.; supervision, R.A.B.; project administration, M.O.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Available online: https://www.genome.gov/genetics-glossary/Race (accessed on 22 July 2022).
  2. Eneanya, N.D.; Boulware, L.E.; Tsai, J.; Bruce, M.A.; Ford, C.L.; Harris, C.; Morales, L.S.; Ryan, M.J.; Reese, P.P.; Thorpe, R.J., Jr.; et al. Health inequities and the inappropriate use of race in nephrology. Nat. Rev. Nephrol. 2022, 18, 84–94. [Google Scholar] [CrossRef]
  3. Biello, K.B.; Rawlings, J.; Carroll-Scott, A.; Browne, R.; Ickovics, J.R. Racial disparities in age at preventable hospitalization among U.S. Adults. Am. J. Prev. Med. 2010, 38, 54–60. [Google Scholar] [CrossRef]
  4. Grams, M.E.; Matsushita, K.; Sang, Y.; Estrella, M.; Foster, M.; Tin, A.; Kao, W.H.; Coresh, J. Explaining the racial difference in AKI incidence. J. Am. Soc. Nephrol. 2014, 25, 1834–1841. [Google Scholar] [CrossRef]
  5. Hsu, R.K.; McCulloch, C.E.; Dudley, R.A.; Lo, L.J.; Hsu, C.Y. Temporal changes in incidence of dialysis-requiring AKI. J. Am. Soc. Nephrol. 2013, 24, 37–42. [Google Scholar] [CrossRef]
  6. Norris, K.C.; Agodoa, L.Y. Unraveling the racial disparities associated with kidney disease. Kidney Int. 2005, 68, 914–924. [Google Scholar] [CrossRef]
  7. Nicholas, S.B.; Kalantar-Zadeh, K.; Norris, K.C. Racial disparities in kidney disease outcomes. Semin. Nephrol. 2013, 33, 409–415. [Google Scholar] [CrossRef]
  8. Lunyera, J.; Clare, R.M.; Chiswell, K.; Scialla, J.J.; Pun, P.H.; Thomas, K.L.; Starks, M.A.; Diamantidis, C.J. Rcial Differences in AKI Incidence Following Percutaneous Coronary Intervention. J. Am. Soc. Nephrol. 2021, 32, 654–662. [Google Scholar] [CrossRef]
  9. Norton, J.M.; Moxey-Mims, M.M.; Eggers, P.W.; Narva, A.S.; Star, R.A.; Kimmel, P.L.; Rodgers, G.P. Social Determinants of Racial Disparities in CKD. J. Am. Soc. Nephrol. 2016, 27, 2576–2595. [Google Scholar] [CrossRef]
  10. Bailey, Z.D.; Krieger, N.; Agénor, M.; Graves, J.; Linos, N.; Bassett, M.T. Structural racism and health inequities in the USA: Evidence and interventions. Lancet 2017, 389, 1453–1463. [Google Scholar] [CrossRef]
  11. KDIGO clinical practice guidelines for acute kidney injury. Kidney Int. 2012, 2, 1–138. [CrossRef]
  12. Chawla, L.S.; Eggers, P.W.; Star, R.A.; Kimmel, P.L. Acute kidney injury and chronic kidney disease as interconnected syndromes. N. Engl. J. Med. 2014, 371, 58–66. [Google Scholar] [CrossRef]
  13. Koulouridis, I.; Price, L.L.; Madias, N.E.; Jaber, B.L. Hospital-acquired acute kidney injury and hospital readmission: A cohort study. Am. J. Kidney Dis. 2015, 65, 275–282. [Google Scholar] [CrossRef] [PubMed]
  14. Rewa, O.; Bagshaw, S.M. Acute kidney injury-epidemiology, outcomes and economics. Nat. Rev. Nephrol. 2014, 10, 193–207. [Google Scholar] [CrossRef] [PubMed]
  15. Hassan, M.O.; Owoyemi, I.; Abdel-Rahman, E.M.; Ma, J.Z.; Balogun, R.A. Association of Race with In-Hospital and Post-Hospitalization Mortality in Patients with Acute Kidney Injury. Nephron 2021, 145, 214–224. [Google Scholar] [CrossRef]
  16. Xue, J.L.; Daniels, F.; Star, R.A.; Kimmel, P.L.; Eggers, P.W.; Molitoris, B.A.; Himmelfarb, J.; Collins, A.J. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J. Am. Soc. Nephrol. 2006, 17, 1135–1142. [Google Scholar] [CrossRef]
  17. Mathioudakis, N.N.; Giles, M.; Yeh, H.C.; Haywood, C.J.; Greer, R.C.; Golden, S.H. Racial differences in acute kidney injury of hospitalized adults with diabetes. J. Diabetes Complicat. 2016, 30, 1129–1136. [Google Scholar] [CrossRef]
  18. Grams, M.E.; Sang, Y.; Ballew, S.H.; Gansevoort, R.T.; Kimm, H.; Kovesdy, C.P.; Naimark, D.; Oien, C.; Smith, D.H.; Coresh, J.; et al. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex with Acute Kidney Injury. Am. J. Kidney Dis. 2015, 66, 591–601. [Google Scholar] [CrossRef]
  19. Womble, T.N.K.J.; Hamilton, D.H.; Shrout, M.A.; Jacobs, C.A.; Duncan, S.T. Greater rates of acute kidney injury in African American total knee arthroplasty patients. J. Arthroplast. 2019, 34, 1240–1243. [Google Scholar] [CrossRef]
  20. Shashaty, M.G.; Meyer, N.J.; Localio, A.R.; Gallop, R.; Bellamy, S.L.; Holena, D.N.; Lanken, P.N.; Kaplan, S.; Yarar, D.; Kawut, S.M.; et al. African American race, obesity, and blood product transfusion are risk factors for acute kidney injury in critically ill trauma patients. J. Crit. Care 2012, 27, 496–504. [Google Scholar] [CrossRef]
  21. Kobayashi, T.; Glorioso, T.J.; Armstrong, E.J.; Maddox, T.M.; Plomondon, M.E.; Grunwald, G.K.; Bradley, S.M.; Tsai, T.T.; Waldo, S.W.; Rao, S.V.; et al. Comparative Outcomes After Percutaneous Coronary Intervention Among Black and White Patients Treated at US Veterans Affairs Hospitals. JAMA Cardiol. 2017, 2, 967–975. [Google Scholar] [CrossRef]
  22. Muiru, A.N.; Yang, J.; Derebail, V.K.; Liu, K.D.; Feldman, H.I.; Srivastava, A.; Bhat, Z.; Saraf, S.L.; Chen, T.K.; He, J.; et al. Black and White Adults with CKD Hospitalized with Acute Kidney Injury: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am. J. Kidney Dis. 2022. [Google Scholar] [CrossRef] [PubMed]
  23. United States Renal Data System. 2018 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2018.
  24. Thakar, C.V.; Liangos, O.; Yared, J.P.; Nelson, D.; Piedmonte, M.R.; Hariachar, S.; Paganini, E.P. ARF after open-heart surgery: Influence of gender and race. Am. J. Kidney Dis. 2003, 41, 742–751. [Google Scholar] [CrossRef]
  25. Liangos, O.; Wald, R.; O’Bell, J.W.; Price, L.; Pereira, B.J.; Jaber, B.L. Epidemiology and outcomes of acute renal failure in hospitalized patients: A national survey. Clin. J. Am. Soc. Nephrol. 2006, 1, 43–51. [Google Scholar] [CrossRef]
  26. Waikar, S.S.; Curhan, G.C.; Ayanian, J.Z.; Chertow, G.M. Race and mortality after acute renal failure. J. Am. Soc. Nephrol. 2007, 18, 2740–2748. [Google Scholar] [CrossRef]
  27. United States Renal Data System. 2012 USRDS Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States; National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2012.
  28. Fisher, M.; Neugarten, J.; Bellin, E.; Yunes, M.; Stahl, L.; Johns, T.S.; Abramowitz, M.K.; Levy, R.; Kumar, N.; Mokrzycki, M.H.; et al. AKI in Hospitalized Patients with and without COVID-19: A Comparison Study. J. Am. Soc. Nephrol. 2020, 31, 2145–2157. [Google Scholar] [CrossRef] [PubMed]
  29. Bjornstad, E.C.; Marshall, S.W.; Mottl, A.K.; Gibson, K.; Golightly, Y.M.; Charles, A.; Gower, E.W. Racial and health insurance disparities in pediatric acute kidney injury in the USA. Pediatr. Nephrol. 2020, 35, 1085–1096. [Google Scholar] [CrossRef]
  30. Beers, K.; Wen, H.H.; Saha, A.; Chauhan, K.; Dave, M.; Coca, S.; Nadkarni, G.; Chan, L. Racial and Ethnic Disparities in Pregnancy-Related Acute Kidney Injury. Kidney360 2020, 1, 169–178. [Google Scholar] [CrossRef] [PubMed]
  31. Heung, M.; Dickinson, T.; Wu, X.; Fitzgerald, D.C.; DeLucia, A., 3rd; Paone, G.; Chores, J.; Nieter, D.; Grix, D.; Theurer, P. The Role of Race on Acute Kidney Injury after Cardiac Surgery. Ann. Thorac. Surg. 2021. [Google Scholar] [CrossRef] [PubMed]
  32. Shah, N.; Koch, S.; Hassouneh, Z.; Bustillo, A.; Simonetto, M.; O’Phelan, K.; Boslet, E. Effect of Race–Ethnicity and CT Angiography on Renal Injury During Blood Pressure Treatment for Intracerebral Hemorrhage. Neurocritical Care 2021, 35, 687–692. [Google Scholar] [CrossRef] [PubMed]
  33. Tzur, S.; Rosset, S.; Shemer, R.; Yudkovsky, G.; Selig, S.; Tarekegn, A.; Bekele, E.; Bradman, N.; Wasser, W.G.; Behar, D.M.; et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 2010, 128, 345–350. [Google Scholar] [CrossRef] [PubMed]
  34. Genovese, G.; Friedman, D.J.; Ross, M.D.; Lecordier, L.; Uzureau, P.; Freedman, B.I.; Bowden, D.W.; Langefeld, C.D.; Oleksyk, T.K.; Uscinski Knob, A.L.; et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010, 329, 841–845. [Google Scholar] [CrossRef]
  35. Privratsky, J.R.; Li, Y.J.; Haynes, C.; Podgoreanu, M.; Mathew, J.; Shah, S.H.; Stafford-Smith, M. Apolipoprotein L1 (APOL1) Coding Variants are Associated with Creatinine Rise After Cardiac Surgery. J. Cardiothorac. Vasc. Anesth. 2020, 34, 3314–3320. [Google Scholar] [CrossRef] [PubMed]
  36. Hung, A.M.; Shah, S.C.; Bick, A.G.; Yu, Z.; Chen, H.C.; Hunt, C.M.; Wendt, F.; Wilson, O.; Greevy, R.A.; Chung, C.P.; et al. APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants with African Ancestry Hospitalized with COVID-19 from the Million Veteran Program. JAMA Intern. Med. 2022, 182, 386–395. [Google Scholar] [CrossRef] [PubMed]
  37. Magoon, S.; Bichu, P.; Malhotra, V.; Alhashimi, F.; Hu, Y.; Khanna, S.; Berhanu, K. COVID-19-Related Glomerulopathy: A Report of 2 Cases of Collapsing Focal Segmental Glomerulosclerosis. Kidney Med. 2020, 2, 488–492. [Google Scholar] [CrossRef] [PubMed]
  38. Kudose, S.; Batal, I.; Santoriello, D.; Xu, K.; Barasch, J.; Peleg, Y.; Canetta, P.; Ratner, L.E.; Marasa, M.; Gharavi, A.G.; et al. Kidney Biopsy Findings in Patients with COVID-19. J. Am. Soc. Nephrol. 2020, 31, 1959–1968. [Google Scholar] [CrossRef] [PubMed]
  39. Kissling, S.; Rotman, S.; Gerber, C.; Halfon, M.; Lamoth, F.; Comte, D.; Lhopitallier, L.; Sadallah, S.; Fakhouri, F. Collapsing glomerulopathy in a COVID-19 patient. Kidney Int. 2020, 98, 228–231. [Google Scholar] [CrossRef] [PubMed]
  40. Larsen, C.P.; Bourne, T.D.; Wilson, J.D.; Saqqa, O.; Sharshir, M.A. Collapsing Glomerulopathy in a Patient with COVID-19. Kidney Int. Rep. 2020, 5, 935–939. [Google Scholar] [CrossRef]
  41. Peleg, Y.; Kudose, S.; D’Agati, V.; Siddall, E.; Ahmad, S.; Nickolas, T.; Kisselev, S.; Gharavi, A.; Canetta, P. Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection. Kidney Int. Rep. 2020, 5, 940–945. [Google Scholar] [CrossRef] [PubMed]
  42. Nadim, M.K.; Forni, L.G.; Mehta, R.L.; Connor, M.J.; Liu, K.D.; Ostermann, M.; Rimmelé, T.; Zarbock, A.; Bell, S.; Bihorac, A.; et al. COVID-19-associated acute kidney injury: Consensus report of the 25th acute disease quality initiative (ADQI) workgroup. Nat. Rev. Nephrol. 2020, 16, 747–764. [Google Scholar] [CrossRef] [PubMed]
  43. Hu, B.; Guo, H.; Zhou, P.; Shi, Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2020, 19, 141–154. [Google Scholar] [CrossRef]
  44. The Lancet Infectious Disease. COVID-19, a pandemic or not? Lancet Infect. Dis. 2020, 20, 383. [Google Scholar] [CrossRef]
  45. Kullar, R.; Marcelin, J.R.; Swartz, T.H.; Piggott, D.A.; Macias Gil, R.; Mathew, T.A.; Kullar, R.; Marcelin, J.R.; Swartz, T.H.; Piggott, D.A.; et al. Racial Disparity of Coronavirus Disease 2019 in African American Communities. J. Infect. Dis. 2020, 222, 890–893. [Google Scholar] [CrossRef] [PubMed]
  46. Risk for COVID-19 Infection H, and Death by Race/Ethnicity. Available online: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html (accessed on 27 July 2022).
  47. Charoenngam, N.; Ilori, T.O.; Holick, M.F.; Hochberg, N.S.; Apovian, C.M. Self-identified Race and COVID-19-Associated Acute Kidney Injury and Inflammation: A Retrospective Cohort Study of Hospitalized Inner-City COVID-19 Patients. J. Gen. Intern. Med. 2021, 36, 3487–3496. [Google Scholar] [CrossRef]
  48. Nimkar, A.; Naaraayan, A.; Hasan, A.; Pant, S.; Durdevic, M.; Suarez, C.N.; Elenius, H.; Hambardzumyan, A.; Lakshmi, K.; Mandel, M.; et al. Incidence and Risk Factors for Acute Kidney Injury and Its Effect on Mortality in Patients Hospitalized from COVID-19. Mayo Clin. Proc. Innov. Qual. Outcomes 2020, 4, 687–695. [Google Scholar] [CrossRef] [PubMed]
  49. Hirsch, J.S.; Ng, J.H.; Ross, D.W.; Sharma, P.; Shah, H.H.; Barnett, R.L.; Barnett, R.L.; Hazzan, A.D.; Fishbane, S.; Jhaveri, K.D.; et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020, 98, 209–218. [Google Scholar] [CrossRef]
  50. Bowe, B.; Cai, M.; Xie, Y.; Gibson, A.K.; Maddukuri, G.; Al-Aly, Z. Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19. Clin. J. Am. Soc. Nephrol. 2021, 16, 14–25. [Google Scholar] [CrossRef]
  51. Phillips, N.; Park, I.W.; Robinson, J.R.; Jones, H.P. The Perfect Storm: COVID-19 Health Disparities in US Blacks. J. Racial Ethn. Health Disparities 2020, 8, 1153–1160. [Google Scholar] [CrossRef]
  52. Vinciguerra, M.; Greco, E. Sars-CoV-2 and black population: ACE2 as shield or blade? Infect. Genet. Evol. 2020, 84, 104361. [Google Scholar] [CrossRef]
  53. Holick, M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357, 266–281. [Google Scholar] [CrossRef]
  54. Charoenngam, N.; Shirvani, A.; Holick, M.F. Vitamin D and Its Potential Benefit for the COVID-19 Pandemic. Endocr. Pract. 2021, 27, 484–493. [Google Scholar] [CrossRef]
  55. Raharja, A.; Tamara, A.; Kok, L.T. Association Between Ethnicity and Severe COVID-19 Disease: A Systematic Review and Meta-analysis. J. Racial Ethn. Health Disparities 2021, 8, 1563–1572. [Google Scholar] [CrossRef] [PubMed]
  56. Nugent, J.; Aklilu, A.; Yamamoto, Y.; Simonov, M.; Li, F.; Biswas, A.; Ghazi, L.; Greenberg, H.; Mansour, G.; Moledina, G.; et al. Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients with and without COVID-19. JAMA Netw. Open 2021, 4, e211095. [Google Scholar] [CrossRef] [PubMed]
  57. Bandelac, L.; Shah, K.D.; Purmessur, P.; Ghazanfar, H.; Nasr, R. Acute Kidney Injury Incidence, Stage, and Recovery in Patients with COVID-19. Int. J. Nephrol. Renov. Dis. 2022, 15, 77–83. [Google Scholar] [CrossRef]
  58. Eneanya, N.D.; Yang, W.; Reese, P.P. Reconsidering the Consequences of Using Race to Estimate Kidney Function. JAMA 2019, 322, 113–114. [Google Scholar] [CrossRef]
  59. Tsai, T.T.; Patel, U.D.; Chang, T.I.; Kennedy, K.F.; Masoudi, F.A.; Matheny, M.E.; Kosiborod, M.; Amin, A.P.; Weintraub, W.S.; Curtis, J.P.; et al. Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: Insights from the National Cardiovascular Data Registry Cath-PCI Registry. J. Am. Heart Assoc. 2014, 3, e001380. [Google Scholar] [CrossRef]
  60. Levey, A.S.; Bosch, J.P.; Lewis, J.B.; Greene, T.; Rogers, N.; Roth, D. A More Accurate Method to Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation. Ann. Intern. Med. 1999, 130, 461–470. [Google Scholar] [CrossRef]
  61. Levey, A.S.; Stevens, L.A.; Schmid, C.H.; Zhang, Y.L.; Castro, A.F., 3rd; Feldman, H.I.; Kusek, J.W.; Eggers, P.; Van Lente, F.; Greene, T.; et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009, 150, 604–612. [Google Scholar] [CrossRef]
  62. Delgado, C.; Baweja, M.; Crews, D.C.; Eneanya, N.D.; Gadegbeku, C.A.; Inker, L.A.; Mendu, M.L.; Miller, W.G.; Moxey-Mims, M.M.; Roberts, G.V.; et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am. J. Kidney Dis. 2022, 79, 268–288. [Google Scholar] [CrossRef]
  63. Inker, L.A.; Eneanya, N.D.; Coresh, J.; Tighiouart, H.; Wang, D.; Sang, Y.; Crews, D.C.; Doria, A.; Estrella, M.M.; Froissart, M.; et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N. Engl. J. Med. 2021, 385, 1737–1749. [Google Scholar] [CrossRef]
  64. Huang, C.; Murugiah, K.; Li, X.; Masoudi, F.A.; Messenger, J.C.; Mortazavi, B.J.; Krumholz, H.M. Effect of removing race correction factor in glomerular filtration rate estimation on predicting acute kidney injury after percutaneous coronary intervention. medRxiv 2022. [Google Scholar] [CrossRef]
  65. Miller, W.G. Uncertainty in estimated glomerular filtration rate is much larger than the race adjustment term. Clin. Chem. 2021, 36, 464–471. [Google Scholar] [CrossRef] [PubMed]
  66. El-Khoury, J.M.; Ovalle, A.A.; Cervinski, M.A.; Levey, A.S.; Jones, G.; Eneanya, N.D.; Lieske, J.C.; Jha, V. Is It Time to Move On? Reexamining Race in Glomerular Filtration Rate Equations. Clin. Chem. 2021, 67, 585–591. [Google Scholar] [CrossRef] [PubMed]
  67. Murray, C.J.; Kulkarni, S.C.; Michaud, C.; Tomijima, N.; Bulzacchelli, M.T.; Iandiorio, T.J.; Ezzati, M. Eight Americas: Investigating mortality disparities across races, counties, and race-counties in the United States. PLoS Med. 2006, 3, e260. [Google Scholar] [CrossRef]
  68. Mensah, G.A.; Mokdad, A.H.; Ford, E.S.; Greenlund, K.J.; Croft, J.B. State of disparities in cardiovascular health in the United States. Circulation 2005, 111, 1233–1241. [Google Scholar] [CrossRef]
  69. United States Renal Data System. 2021 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States//Chronic Kidney Disease//4: Acute Kidney Injury; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2021. [CrossRef]
  70. Lertdumrongluk, P.; Streja, E.; Rhee, C.M.; Moradi, H.; Chang, Y.; Reddy, U.; Tantisattamo, E.; Kalantar-Zadeh, K.; Kopp, J.B. Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1. Cardiorenal Med. 2019, 9, 212–221. [Google Scholar] [CrossRef]
  71. Kahn, D.F.; Duffy, S.J.; Tomasian, D.; Holbrook, M.; Rescorl, L.; Russell, J.; Gokce, N.; Loscalzo, J.; Vita, J.A. Effects of black race on forearm resistance vessel function. Hypertension 2002, 40, 195–201. [Google Scholar] [CrossRef]
  72. Kalinowski, L.; Dobrucki, I.T.; Malinski, T. Race-specific differences in endothelial function: Predisposition of African Americans to vascular diseases. Circulation 2004, 109, 2511–2517. [Google Scholar] [CrossRef]
  73. Zitouni, K.; Nourooz-Zadeh, J.; Harry, D.; Kerry, S.M.; Betteridge, D.J.; Cappuccio, F.P.; Earle, K.A. Race-specific differences in antioxidant enzyme activity in patients with type 2 diabetes: A potential association with the risk of developing nephropathy. Diabetes Care 2005, 28, 1698–1703. [Google Scholar] [CrossRef][Green Version]
  74. Crews, D.C.; Sozio, S.M.; Liu, Y.; Coresh, J.; Powe, N.R. Inflammation and the paradox of racial differences in dialysis survival. J. Am. Soc. Nephrol. 2011, 22, 2279–2286. [Google Scholar] [CrossRef]
  75. Parr, S.K.; Matheny, M.E.; Abdel-Kader, K.; Greevy, R.A., Jr.; Bian, A.; Fly, J.; Chen, G.; Speroff, T.; Hung, A.M.; Ikizler, T.A.; et al. Acute kidney injury is a risk factor for subsequent proteinuria. Kidney Int. 2018, 93, 460–469. [Google Scholar] [CrossRef]
  76. Zarkowsky, D.S.; Arhuidese, I.J.; Hicks, C.W.; Canner, J.K.; Qazi, U.; Obeid, T.; Schneider, E.; Abularrage, C.J.; Freischlag, J.A.; Malas, M.B. Racial/Ethnic Disparities Associated with Initial Hemodialysis Access. JAMA Surg. 2015, 150, 529–536. [Google Scholar] [CrossRef] [PubMed]
  77. Boulware, L.E.; Purnell, T.S.; Mohottige, D. Systemic Kidney Transplant Inequities for Black Individuals: Examining the Contribution of Racialized Kidney Function Estimating Equations. JAMA Netw. Open 2021, 4, e2034630. [Google Scholar] [CrossRef] [PubMed]
  78. Jungers, P. Late referral: Loss of chance for the patient, loss of money for society. Nephrol. Dial. Transplant. 2002, 17, 371–375. [Google Scholar] [CrossRef] [PubMed][Green Version]
  79. Ifudu, O.; Dawood, M.; Homel, P.; Friedman, E.A. Excess morbidity in patients starting uremia therapy without prior care by a nephrologist. Am. J. Kidney Dis. 1996, 28, 841–845. [Google Scholar] [CrossRef]
  80. Ford, C.L.; Airhihenbuwa, C.O. Commentary: Just what is critical race theory and what’s it doing in a progressive field like public health? Ethn. Dis. 2018, 28, 223–230. [Google Scholar] [CrossRef]
  81. Ford, C.L.; Airhihenbuwa, C.O. Critical race theory, race equity, and public health: Toward antiracism praxis. Am. J. Public Health 2010, 100, S30–S35. [Google Scholar] [CrossRef]
  82. Vyas, D.A.; Eisenstein, L.G.; Jones, D.S. Hidden in plain sight—Reconsidering the use of race correction in clinical algorithms. N. Engl. J. Med. 2020, 383, 874–882. [Google Scholar] [CrossRef]
Jcm 11 05822 g001
Figure 1. Sociocultural influences on racial/ethnic minority health with implications for progression of acute kidney injury to chronic kidney disease. Adapted with permission from Ref. [6]. 2022, Elsevier.
Figure 1. Sociocultural influences on racial/ethnic minority health with implications for progression of acute kidney injury to chronic kidney disease. Adapted with permission from Ref. [6]. 2022, Elsevier.
Jcm 11 05822 g001
Table 1. Studies summarizing incidence, management, and outcomes of AKI in Black and White races.
Table 1. Studies summarizing incidence, management, and outcomes of AKI in Black and White races.
StudyDesignClinical
Setting		Population CharacteristicsAKI
Definition		AKI Rates/Risks (Black vs. White)ManagementOutcomes
Thakar et al., 2003 [24]Observational cohort studyDatabase of the Department of Cardiothoracic Anesthesiology, ClevelandOpen-heart surgery patients (n = 22,589)50% reduction or greater decline in GFR relative to baseline or ARF requiring dialysis2.94% vs. 1.80%Dialysis (not specified)ARF and all-cause postoperative mortality
Liangos et al., 2006 [25]Observational cohort studyNational
Hospital Discharge Survey database		Hospitalized adult patients (n = 29,039,599)ICD-9-CM codesARF more common in Black patients (Data not available)Dialysis (not specified)Hospital length of stay, dialysis requirement, hospital death
Xue et al., 2006 [16]Observational cohort studyMedicare beneficiaries, 1992 to 2001Hospitalized patients (n = 5,403,015)ICD-9-CM codes34.4 vs. 22.3 cases per 1000 discharges Dialysis (not specified)ARF, sepsis, ICU stay, other acute organ failure, and death within 90 days after admission
Waikar et al., 2007 [26]Observational cohort studyNationwide Inpatient SampleHospitalized adults (n = 15,820,871)ICD-9-CM codes3.1% vs. 2.4%HD and CRRTIn-hospital mortality
USRDS ADR, 2012 [27]Observational cohort studyMedicare, MarketScan, and Ingenix i3 populationsHospitalized adult patients (n = 1,201,064)ICD-9-CM codes44.2 vs. 24.3 per 1000 patient yearsPD, continuous HD, intermittent HD, daily HDRecurrent hospitalization, ESRD, Death
USRDS ADR 2018 [23]Observational cohort studyMedicare, Optum Clinformatics™, Veterans Affairs populationHospitalized adult patients (n = 854,990)ICD-9-CM codes and KDIGOMedicare (34.3% vs. 23.0%), Optum Clinformatics™ (9.4% vs. 7.4%), Veterans Affairs (30.4% vs. 24.1%) -Recurrent AKI hospitalization (Optum Clinformatics™), ESRD, and Death
Hsu et al., 2013 [5]Observational cohort studyNationwide Inpatient SampleHospitalized patients with dialysis-requiring AKI (n = 1,095,000)ICD-9-CM codes15.6% vs. 10.2%Dialysis (not specified)Dialysis-requiring AKI
Grams et al., 2014 [4]Prospective, community-based cohort studyARIC studyIndividuals aged 45–64 years (n = 10,588)ICD-9-CM codes7.4 vs. 5.8 cases per 1000 person-years-Hospitalization, follow-up time on ACEI/ARB, and Death
Mathioudakis et al., 2016 [17]Observational cohort studyNational Hospital Discharge Survey databaseHospitalized adults with diabetes (n = 276,138)ICD-9-CM codes6.0% vs. 4.6%Dialysis (not specified)AKI, in-hospital mortality, and length of hospital stay
Fisher et al., 2020 [28]Retrospective observational studyNew York City Health SystemHospitalized adult patients with or without COVID-19 (n = 9859)KDIGO42.0% vs. 9.6%CRRT, PIRRT, PD, HDIncident AKI, composite need for RRT or mortality.
Bjornstad et al., 2020 [29]Secondary analysis study2012 Kids’ Inpatient DatabaseHospitalized pediatric patients aged 1–20 years (n = 1,699,841)ICD-9-CM codesRisks: 13.4 vs. 12.4-AKI
Beers et al., 2020 [30]Retrospective cohort studyNational Inpatient Sample Patients with pregnancy-related hospitalizations (n = 48,316,430)ICD-9-CM codes29% vs. 13%-In-hospital mortality, adverse discharge, pregnancy-related complications such as miscarriage, preterm labor, and preeclampsia/eclampsia
Hassan et al., 2021 [15]Observational cohort studyClinical data repository, UVA Health SystemHospitalized adults with AKI (n = 386,342)KDIGO3.6 vs. 4.2 cases per 10 person-yearsDialysis (not specified)In-hospital mortality and post-hospitalization mortality
Heung et al., 2021 [31]Observational cohortPerfusion Measures and Outcomes (PERForm) RegistryAdult cardiac surgical patients (n = 34,520)Serum creatinine-based criteria8% vs. 5%-Post-operative AKI
Shah et al., 2021 [32]RetrospectiveJackson Memorial Hospital databasePatients with ICH hemorrhage and CT angiogram (n = 394)KDIGO19% vs. 17%-AKI
Lunyera et al., 2021 [8]Observational cohort studyDuke Databank for Cardiovascular DiseasePatients undergoing percutaneous coronary intervention (n = 9422)KDIGO14% vs. 8%-AKI incidence, AKI severity, AKI requiring dialysis, and contrast-induced nephropathy
Muiru et al., 2022 [22]Multicenter prospective cohort studyChronic Renal Insufficiency Cohort (CRIC) StudyParticipants with CKD hospitalized with AKI (n = 2720)≥50% increase from nadir to peak serum creatinine6.3 vs. 5.3 per 100 person-years-Hospitalized AKI
AKI, acute kidney injury; ARF, acute renal failure; GFR, glomerular filtration rate, CRRT, continuous renal replacement therapy; PIRRT, prolonged intermittent RRT; PD, peritoneal dialysis; HD, hemodialysis; ICD-9-CM, international classification of diseases, ninth revision, clinical modification; ICU, intensive care unit; USRDS ADR, united states renal data system annual data system; ESRD, end-stage renal disease; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARIC, atherosclerosis risk in communities; KDIGO, kidney disease: improving global outcomes; UVA, university of Virginia; ICH, intracranial hemorrhage; CT, computer tomography, CRIC, chronic renal insufficiency cohort.
Table 2. Summary of studies showing association between race and COVID-19-induced AKI.
Table 2. Summary of studies showing association between race and COVID-19-induced AKI.
StudyDesignClinical SettingPopulation CharacteristicsAKI
Definition		Patients with AKIRisk of AKIOutcomes
Fisher et al., 2020 [28]Retrospective observational studyNew York City Health SystemHospitalized adult patients with or without COVID-19 (n = 9859)KDIGOBlack (40.5%), White (8.2%), Hispanic (33.5%), Other (17.8%)Black race was associated with AKI (adjusted odds ratio, 1.7; 95% CI, 1.3 to 2.3)Incident AKI, composite need for RRT or mortality
Hirsch et al., 2020 [49]Retrospective observational cohort studyNew York Health SystemHospitalized adult COVID-19-positive patients (n = 5449)KDIGOBlack (20.8%), White (41.0%), Asian (8.1%), Mixed (25.4%), Other (4.2%), Declined (0.4%)Black race was an independent predictor of AKI (adjusted odds ratio, 1.23; 95% CI, 1.01 to 1.50)Development of AKI, or RRT and hospital disposition (i.e., discharge or death)
Nimkar et al., 2020 [48]Retrospective case seriesNew York City metropolitan teaching hospitalHospitalized confirmed adult COVID-19 patients (n = 370)KDIGOBlack (43%), White (33.5%), Hispanic (14.5%), Other (8.9%)African American race showed higher odds of AKI (adjusted odds ratio, 2.1; 95% CI, 1.2 to 3.7AKI and mortality
Raharja et al., 2021 [55]Systematic review and meta-analysisMEDLINE, EMBASE, Cochrane, WHO COVID-19 databasesSeventy-two articles with COVID-19-positive participants (n = 17,950,989)-White (38%), Black (38%), Asian (5.2%), Hispanic (9.1%), Mixed/other (13%) Unadjusted analysis showed Black ethnicity had a significantly higher risk of AKI (RR: 1.35, 95% CI: 1.04–1.76), but pooled RR was non-significant (RR: 1.60, 95% CI: 0.89–2.90)All-cause mortality, hospitalization, critical care admission, invasive mechanical ventilation, extracorporeal membrane oxygenation, and AKI
Bowe et al., 2021 [50]Observational cohort studyUS Veterans Affairs populationHospitalized COVID-19 patients (n = 5216)KDIGOBlack (53%), White (42%), Other (5%)Black race was a significant predictor of AKI (adjusted odds ratio, 1.93; 95% CI, 1.69 to 2.20)All-cause mortality, discharge, need for mechanical ventilation, hospital length of stay
Charoenngam et al., 2021 [47]Single-center retrospective cohort studyBoston Medical CenterHospitalized adults with a positive SARS-CoV-2 PCR test (n = 1424)ICD-10-CM codes Black (39.4%), White (23.1%)AKI was statistically significantly associated with Black race (adjusted odds ratio, 2.16; 95% CI, 1.57 to 2.97) In-hospital mortality, intensive care unit admission, hospital morbidities, and inflammatory marker levels
Nugent et al., 2021 [56]Retrospective cohort studyYale New Haven Health System networkHospitalized adult patients with positive COVID-19 and AKI; discharged and did not require dialysis within 3 days of discharge (n = 182)KDIGOBlack (40.1%), White (40.7%), Asian (2.7%), Hispanic (22%), Other (16.5%)-Association between COVID-19-associated AKI and eGFR slope after discharge and time to AKI recovery
Bandelac et al., 2022 [57]Retrospective studyThe BronxCare Health SystemHospitalized adults with a positive SARS-CoV-2 PCR test (n = 1545)KDIGOBlack (31.9%), White (1.6%), Hispanic (58.1%), Other (8.4%)-AKI, incidence, mortality, stage, and recovery of AKI
AKI, acute kidney injury; KDIGO, kidney disease: improving global outcomes; CRRT, continuous renal replacement therapy; PIRRT, prolonged intermittent RRT; PD, peritoneal dialysis; HD, hemodialysis; ICD-10-CM, international classification of diseases, tenth revision, clinical modification; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RR, relative risk.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Hassan, M.O.; Balogun, R.A. The Effects of Race on Acute Kidney Injury. J. Clin. Med. 2022, 11, 5822. https://doi.org/10.3390/jcm11195822

AMA Style

Hassan MO, Balogun RA. The Effects of Race on Acute Kidney Injury. Journal of Clinical Medicine. 2022; 11(19):5822. https://doi.org/10.3390/jcm11195822

Chicago/Turabian Style

Hassan, Muzamil Olamide, and Rasheed Abiodun Balogun. 2022. "The Effects of Race on Acute Kidney Injury" Journal of Clinical Medicine 11, no. 19: 5822. https://doi.org/10.3390/jcm11195822

APA Style

Hassan, M. O., & Balogun, R. A. (2022). The Effects of Race on Acute Kidney Injury. Journal of Clinical Medicine, 11(19), 5822. https://doi.org/10.3390/jcm11195822

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop